share_log

HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Lowers Price Target to $27

Benzinga ·  May 9 15:03

HC Wainwright & Co. analyst Douglas Tsao maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $37 to $27.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment